KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (Weighted Average) (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Shares Outstanding (Weighted Average) readings, the most recent being $132.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.48% to $132.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $132.9 million, a 2.48% increase, with the full-year FY2025 number at $131.0 million, up 2.63% from a year prior.
  • Shares Outstanding (Weighted Average) hit $132.9 million in Q1 2026 for Alnylam Pharmaceuticals, up from $131.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $132.9 million in Q1 2026 to a low of $120.4 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $126.1 million (2024), compared with a mean of $126.2 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 3.35% in 2023 and later increased 1.55% in 2024.
  • Alnylam Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $121.7 million in 2022, then rose by 2.64% to $124.9 million in 2023, then grew by 2.2% to $127.7 million in 2024, then rose by 2.63% to $131.0 million in 2025, then increased by 1.44% to $132.9 million in 2026.
  • The last three reported values for Shares Outstanding (Weighted Average) were $132.9 million (Q1 2026), $131.0 million (Q4 2025), and $130.6 million (Q3 2025) per Business Quant data.